2025 ICD-10-CM code D07.1
(Active) Effective Date: N/A Neoplasms - In situ neoplasms (D00-D09) 2 Neoplasms (C00-D49) Feed
Carcinoma in situ of vulva.
Medical necessity is based on the presence of precancerous cells in the vulva confirmed by biopsy, the potential for progression to invasive cancer, and the chosen treatment modality.
Diagnosis involves a gynecological pelvic exam, vulvar biopsy, Pap smear, and pelvic ultrasound. Treatment options include LEEP, cold knife cone biopsy, cryosurgery, laser surgery, hysterectomy, or vulvectomy, depending on the severity.
In simple words: Carcinoma in situ (CIS) of the vulva is a pre-cancerous condition where abnormal cells are found on the surface of the vulva.These cells haven't spread yet, but could develop into cancer if not treated.It's often linked to HPV infection.
Carcinoma in situ of the vulva is a stage 0 disease, characterized by the abnormal growth of cells localized to the vulva. These cells have not yet spread to other areas but have the potential to develop into invasive cancer. It's often associated with HPV infection, genital warts, obesity, and estrogen replacement therapy.
Example 1: A 60-year-old female with a history of HPV presents with vulvar itching and a white plaque. Biopsy confirms VIN III., A 70-year-old female with lichen sclerosus undergoes a biopsy, which reveals differentiated VIN., A 55-year-old obese female on estrogen replacement therapy presents with abnormal vaginal bleeding. Examination and biopsy reveal CIS of the vulva.
Medical history, including HPV status and other risk factors, physical exam findings, biopsy results confirming VIN III, and details of any procedures performed.
** Distinguish between different VIN grades and ensure proper documentation of the diagnosis. For cases with invasion, refer to the C51 series for appropriate coding.
- Specialties:Gynecology, Oncology, Pathology
- Place of Service:Office, Outpatient Hospital, Inpatient Hospital